JP2008063289A - Promoter of increase in adiponectin level in blood and/or reduction inhibitor - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an increase promoter and/or a reduction inhibitor of adiponectin level in blood and a food and drink and a feed for promoting an increase and/or inhibiting a reduction in the adiponectin level in blood. <P>SOLUTION: The increase promoter and/or reduction inhibitor of the adiponectin level in blood comprise a cultured product of a lactic acid bacterium of the genus Lactobacillus, above all, Lactobacillus gasseri and Lactobacillus helveticus or a bacterial cell itself thereof as an active ingredient. The food and drink and feed for promoting the increase and/or inhibiting the reduction in the adiponectin level in blood comprise the cultured product of the lactic acid bacterium of the genus Lactobacillus and/or bacterial cell thereof as the active ingredient. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

  The present invention relates to the promotion of an increase in the concentration of adiponectin in the blood comprising, as an active ingredient, a Lactobacillus gasseri or Lactobacillus helveticus culture and / or cell body, among others, Lactobacillus lactic acid bacteria. The present invention relates to a reduction inhibitor, a novel food / beverage product imparted with a blood adiponectin concentration increase promotion and / or a decrease suppression effect, and a novel feed that imparted a blood adiponectin concentration increase promotion and / or a decrease suppression effect. The blood adiponectin concentration increase promoting and / or decreasing inhibitor of the present invention can promote and / or suppress the increase of blood adiponectin concentration by ingestion. The decrease in blood adiponectin concentration is considered to be the cause of metabolic syndrome that is said to be related to the development of future cardiovascular diseases such as thrombosis, insulin resistance, abnormal glucose metabolism, and hypertension. Effective for prevention and treatment.

  In recent years, with the shift of lifestyle habits to Europe and the United States, the population exhibiting pathological conditions such as diabetes, hypertension, hyperlipidemia, and arteriosclerosis, which are lifestyle-related diseases, is increasing. In particular, deaths due to cardiovascular and cerebrovascular diseases account for about one-third of the causes of death, and the number of deaths is increasing year by year. These arteriosclerotic diseases are significantly increased in risk of onset due to accumulation of risk factors such as hypertension, hyperlipidemia and impaired glucose tolerance. This state of accumulation of risk factors is called metabolic syndrome and has been widely recognized. According to a survey of 120,000 Japanese corporate workers, “obesity”, “hypertension”, “hyperglycemia”, “high triglyceride (triglyceridemia)” or “hypercholesterolemia” People who have one risk factor are said to be five times as likely to develop heart disease, people who have two have 10 times the risk, and people who have three or four have 31 times the risk. According to a survey by the Ministry of Health, Labor and Welfare, the number of hypertensive patients was 39 million, hyperlipidemia was 22 million, diabetes (including the reserve army) was 16.2 million, and obesity was 4.68 million. The number of patients is increasing year by year.

  Metabolic syndrome is `` a pathological condition that tends to cause arteriosclerosis in multiple risk factor syndrome, which is a combination of insulin resistance and glucose metabolism abnormality, lipid metabolism abnormality, hypertension based on the accumulation of visceral fat, and on the basis of it. '' The decrease in blood adiponectin concentration associated with the accumulation of visceral fat is a fundamental factor in metabolic syndrome and arteriosclerosis. Adipose tissue, the largest secretory tissue in the living body, produces various endocrine factors and is involved in maintaining homeostasis in the living body. However, it has been found that excessive accumulation of visceral fat disrupts the secretion balance of endocrine factors and causes various pathological conditions. In particular, endocrine factors such as plasminogen activator inhibitor (PAI-1), tumor necrosis factor (TNF-α), and leptin increase in secretion amount as visceral fat accumulates, resulting in thrombosis, insulin resistance, Causes abnormal glucose metabolism, high blood pressure, etc. On the other hand, adiponectin, which is secreted specifically by adipose tissue, is usually present in a high concentration in the blood, but it is known that its concentration decreases with the accumulation of visceral fat. Adiponectin is known to have various physiological functions such as anti-diabetes, anti-arteriosclerosis, anti-inflammatory action, and anti-hypertension, and promotes increase of adiponectin concentration or suppresses decrease of adiponectin concentration in blood It is very important to prevent and treat metabolic syndrome.

  Conventionally, pharmacotherapy is also used as a countermeasure for individual pathological conditions of metabolic syndrome, but there are problems such as the need for prescription and side effects. Furthermore, it has been found that even if treatment for one pathological condition is performed, other pathological conditions lead to development of serious pathological conditions, and endocrine factors derived from adipocytes existing upstream of these conditions It becomes necessary to adjust the secretion balance. For this reason, reviewing daily life such as exercise therapy and diet therapy is more important than drug therapy for the prevention and treatment of metabolic syndrome caused by visceral fat accumulation. Therefore, a food and drink that can be ingested on a daily basis and is highly safe even when ingested over a long period of time and effective for the prevention and treatment of metabolic syndrome caused by the accumulation of visceral fat is desired.

  For substances that promote the increase in adiponectin concentration in blood, apple extract (see, for example, Patent Document 1), hop koji extract (for example, see Patent Document 2), green tea catechin (see, for example, Patent Document 3). ), Rice bran extract (for example, see Patent Document 4), and turmeric rhizome extract (for example, see Patent Document 5), many plant-derived extracts are disclosed. However, some of these have complicated extraction conditions, and some have restrictions on the availability of extraction raw materials, and there is a concern about stable supply as a formulation or a food and beverage blending raw material. It is not known that the culture of bacteria or the cells themselves have an effect of promoting an increase in adiponectin concentration and / or suppressing a decrease.

  Lactobacillus gasseri has a pathogen infection protective action (for example, see Patent Document 6), an inflammatory bowel disease and irritable bowel syndrome preventive action (for example, Patent Document 7), and a diabetic complication preventive action. (See, for example, Patent Document 8), serum cholesterol elevation-inhibiting action (for example, see Patent Document 9), bone resorption-inhibiting action (for example, see Patent Document 10), immune enhancing action (for example, see Patent Document 11). ) Etc. are known. However, it is not known at all that the fermented product of Lactobacillus gasseri, or the microbial cell itself, has a blood adiponectin concentration increase promoting action and a decrease suppressing action.

Lactobacillus helveticus (Lactobacillus helveticus) has long been used as a typical lactic acid bacteria starter for dairy dairy products. Lactobacillus helveticus has a strong proteolytic activity, and an extracellular proteinase having a particularly high activity plays an important role on the fermentability of milk. That is, extracellular proteinase degrades milk protein to produce various peptide fragments. The generated peptide is subjected to the action of the peptidase group to become a peptide having a lower molecular weight. It is known that a part of the peptide produced in the medium by the action of the proteolytic enzyme group is taken into the lactic acid bacteria and used as a nitrogen source. On the other hand, it has been reported that peptides produced in the medium have an inhibitory activity against angiotensin converting enzyme (hereinafter referred to as ACE), which is a causative substance of blood pressure raising action ( For example, refer nonpatent literature 1.). As for peptides aimed at inhibiting the enzyme activity of ACE and suppressing the increase in blood pressure, many effective peptides have already been reported from milk protein, soybean protein, fish protein degradation products, etc., but Lactobacillus helvetica It is natural that peptides having ACE inhibitory activity in fermented milk using Lactobacillus helveticus are Val-Pro-Pro and Ile-Pro-Pro, and that these lactotripeptides have a strong antihypertensive action. It has been confirmed by experiments using onset hypertensive rats (SHR) (see, for example, Non-Patent Document 2). Furthermore, it has been suggested that lactotripeptide has a stress relieving action in addition to blood pressure lowering activity (see, for example, Patent Documents 12 and 13). Lactobacillus helveticus is known to have an immunostimulatory effect (see, for example, Patent Document 14). However, it is not known at all that the fermented product of Lactobacillus helveticus, or the fungus body itself, has a blood adiponectin concentration increase promoting action and a decrease suppressing action.
JP 2006-193502 A JP 2006-193501 A JP 2006-131512 A JP 2005-68132 A JP 2005-60308 A JP-A-8-268899 JP 2003-95963 A Japanese Patent Laid-Open No. 2003-252770 Japanese Patent Laid-Open No. 2003-306436 Japanese Patent Laid-Open No. 2004-315477 JP 2006-69993 A Japanese Patent Laid-Open No. 10-45610 Japanese Patent Laid-Open No. 11-98978 JP 2006-76961 A J. Dairy Sci., 78: 777-783 (1995) J. Dairy Sci., 78: 1253-1257 (1995)

  The present invention can be taken daily and promotes an increase in blood adiponectin concentration effective for prevention and treatment of metabolic syndrome that promotes and / or suppresses an increase in blood adiponectin concentration. An object of the present invention is to provide a decrease inhibitor, a food and drink and a feed provided with these functions.

  The present inventors have been diligently searching for a component that does not decrease the concentration of adiponectin, which is said to increase the risk of cardiovascular disease when the concentration in the blood is reduced from among the milk components. As a result, Lactobacillus genus lactic acid bacteria, in particular, Lactobacillus gasseri and Lactobacillus helveticus cultures, or the cells themselves, have a very high blood adiponectin concentration increase promotion and / or It has been found that it has a decrease-inhibiting action, and the present invention has been completed.

Accordingly, the present invention is an invention having the following configuration.
(1) A blood adiponectin concentration increase promoter and / or a decrease inhibitor comprising a culture of Lactobacillus lactic acid bacteria and / or bacterial cells as an active ingredient.
(2) Lactobacillus lactic acid bacteria are Lactobacillus gasseri or Lactobacillus helveticus, (1) The blood adiponectin concentration increase promotion and / or decrease inhibitor.
(3) A food / beverage product for promoting and / or suppressing decrease in blood adiponectin concentration, comprising a culture of Lactobacillus genus lactic acid bacteria and / or bacterial cells as an active ingredient.
(4) Lactobacillus lactic acid bacterium is Lactobacillus gasseri or Lactobacillus helveticus, (3) The blood adiponectin concentration increase promotion and / or decrease suppression food / beverage products.
(5) A feed for promoting and / or suppressing decrease in blood adiponectin concentration, comprising a culture of Lactobacillus genus lactic acid bacteria and / or bacterial cells as active ingredients.
(6) Lactobacillus lactic acid bacteria is Lactobacillus gasseri or Lactobacillus helveticus, (5) The blood adiponectin concentration increase promotion and / or decrease suppression feed.

  The blood adiponectin concentration increase promoting and / or decreasing inhibitor of the present invention, and the food and drink and feed imparted with the blood adiponectin concentration increasing promoting and / or decreasing suppressing action are said to be metabolic syndrome, which is said to develop due to a decrease in blood adiponectin It is effective for prevention and treatment. Further, the blood adiponectin concentration increase promoting and / or decreasing inhibitor of the present invention, and the food and drink and the feed imparted with the blood adiponectin concentration increasing promotion and / or decrease inhibiting action are Lactobacillus lactic acid bacteria, among others Lactobacillus gasseri (Lactobacillus helveticus) culture, or its cell itself is used, so it can be supplied in large quantities at a relatively low cost and is extremely safe. Have.

  Among the many lactic acid bacteria derived from fermented milk and humans, the present inventors have high gastric acid tolerance, good growth under low pH conditions, high human intestinal cell affinity and high human intestinal tract affinity. The selection of strains that are resistant to bile acids, colonize in the intestinal tract, have high survival when applied to foods, and have excellent flavor and physical properties has been promoted. Next, among the lactic acid bacteria showing high colonization in the human intestinal tract, the selection is made under the condition of promoting and / or suppressing the decrease of blood adiponectin concentration, and the lactic acid bacteria belonging to the genus Lactobacillus, especially Lactobacillus gasseri It has been found that lactic acid bacteria belonging to (Lactobacillus gasseri) or Lactobacillus helveticus have a blood adiponectin concentration increase promotion and / or a decrease suppression effect. Lactobacillus gasseri SBT2055 strain, Lactobacillus gasseri JCM1131 strain, and Lactobacillus gasseri ATCC19992 strain are selected from lactic acid bacteria belonging to Lactobacillus gaselli as strains meeting the above conditions We were able to. The SBT2055 strain has been deposited at the National Institute of Advanced Industrial Science and Technology Patent Microorganism Deposit Center under the deposit number FERM P-15535. The JCM1131 strain is a public strain of RIKEN, and the ATCC19992 strain is a public strain of the American Type Culture Collection.

  Moreover, among the lactic acid bacteria belonging to Lactobacillus helveticus as strains meeting the above conditions, Lactobacillus helveticus (Lactobacillus helveticus) SBT2171 strain, Lactobacillus helveticus (Lactobacillus helveticus) ATCC10386 strain and Lactobacillus helveticus (Lactobacillus helveticus) ) The ATCC10797 strain could be selected. In this case, the effects of the present invention could be expected for both live and dead bacteria. The SBT2171 strain has been deposited at the National Institute of Advanced Industrial Science and Technology Patent Microorganism Deposit Center under the deposit number FERM P-14381. The ATCC 10386 strain and ATCC 10797 strain are public strains of the American Type Culture Collection.

  In particular, Lactobacillus gasseri strain SBT2055 has a high affinity for human intestinal cells, and can survive and reach the intestinal tract when administered orally. It has a high activity that acts on the host by growing in the intestinal tract and has an effect of promoting an increase in blood adiponectin concentration and / or a decrease in decrease. Lactobacillus gasseri (Lactobacillus gasseri) administered from outside the body has been established in the intestine and exhibits no such physiological effect, and has been revealed for the first time by the present inventors. Furthermore, in the present invention, not only the above-mentioned strains but also Lactobacillus gasseri isolated from humans and fermented milk, and not only live bacteria but also dead cells, exhibit the above action Any one can be used. In addition, a mutant strain of Lactobacillus gasseri that exhibits the above action can also be used. As the Lactobacillus gasseri medium of the present invention, various media such as a milk medium or a medium containing a milk component, and a semi-synthetic medium not containing this can be used. An example of such a medium is a reduced skim milk medium obtained by reducing skim milk and then heat sterilizing.

  These Lactobacillus lactic acid bacteria are cultured by static culture or neutralized culture with a constant pH, but the culture method is not particularly limited as long as the bacteria grow well. Bacteria are cultured according to a conventional method for lactic acid bacteria culture, and those isolated from the obtained culture by means of collection such as centrifugation can be used as they are as the active ingredient of the present invention. In addition to cells that have been purely isolated as cells, cultures, fermented products, suspensions, other cell-containing materials, and cytoplasm and cells that have been processed using enzymes or physical means Wall fractions can also be used.

  The blood adiponectin concentration increase promoting and / or decreasing inhibitor of the present invention comprises a culture of Lactobacillus lactic acid bacteria and / or the cells themselves as active ingredients. Furthermore, in formulating, excipients, stabilizers, flavoring agents, and the like that are permitted in the formulation are appropriately mixed and concentrated, freeze-dried, or heat-dried to form dead cells. These dried products, concentrates, and pastes are also included. In addition, it is formulated by mixing excipients, binders, disintegrants, lubricants, flavoring agents, suspending agents, coating agents, and other optional agents as long as they do not interfere with the action of the cells or culture. It can also be converted. The dosage form can be tablets, pills, capsules, granules, powders, powders, syrups, etc., and these are preferably administered orally.

In addition, the present invention provides an increased concentration of adiponectin in the blood containing, as an active ingredient, a lactobacillus genus lactic acid bacterium, in particular, a fermented product of Lactobacillus gasseri and Lactobacillus helveticus, or the cell itself. It is the food / beverage product which provided the function of promotion and / or reduction suppression. The food and drink provided with the blood adiponectin concentration increase accelerating and / or suppressing effect of the present invention include lactic acid bacteria belonging to the genus Lactobacillus, among others, Lactobacillus gasseri and Lactobacillus helveticus (Lactobacillus helveticus). Product or fermented product, or the microbial cell itself, or a food or drink containing the microbial cell, culture, or fermented product itself. Fermented foods such as yogurt and cheese are suitable as the form of the culture or fermented product. The microbial cells, culture or fermented product may be blended in any food or drink, and may be added to the raw material during the production process of the food or drink. Examples of foods and drinks include milk drinks, fermented milk, fruit juice drinks, jelly, candy, dairy products, processed egg products such as mayonnaise, and foods such as confectionery and breads such as butter cake. Moreover, what was mix | blended with the nutritional composition intended for infants, an infant, a low birth weight infant, etc. other than various milk powder can be illustrated. When used as a living cell, it is obtained by fermenting a Lactobacillus genus lactic acid bacterium, in particular, a Lactobacillus gasseri and Lactobacillus helveticus strain itself, and the lactic acid bacterium. The obtained fermented milk or cheese may be used as a raw material to make bread, snacks, cakes, puddings, etc. for promoting and / or suppressing decrease in blood adiponectin concentration. These can be ingested on a daily basis and have the effect of promoting the increase in blood adiponectin concentration and / or suppressing the decrease in blood adiponectin, and thus are effective in the prevention and treatment of metabolic syndrome caused by a decrease in blood adiponectin.
Furthermore, the present invention provides an increase in the concentration of adiponectin in the blood comprising as an active ingredient a lactic acid bacterium belonging to the genus Lactobacillus, in particular, a fermented product of Lactobacillus gasseri and Lactobacillus helveticus, or the cell itself. It is a feed provided with a function of promoting and / or suppressing decrease. As a feed for livestock, as in the case of the above-mentioned food and drink, the fungus body, culture or fermented product may be blended in any feed, and may be added to the raw material during the production process of the food or drink.

In the present invention, 10 to 200 g of a culture of Lactobacillus gasseri and Lactobacillus helveticus is used in the case of an adult in order to exert a blood adiponectin concentration increase promoting and / or suppressing effect. Alternatively, the blending amount and the like may be adjusted so that 0.1 to 5,000 mg of the cells per day can be ingested. The content ratio of lactic acid bacteria is not particularly limited, and may be appropriately adjusted in accordance with ease of production, a preferable daily dose, and the like. For example, when the dosage form is liquid, it is preferably 1 × 10 ⁵ cells / ml to 1 × 10 ¹⁰ cells / ml, and when solid, 1 × 10 ⁵ cells / g to 1 × 10 ¹⁰ cells / g is preferable. When administered as a living bacterium, the intended effect of the present invention can be exhibited by administering 10 ⁸ to 10 ¹² cfu / day per adult. By taking in this way, it settles in the intestinal tract and exhibits the desired effect.

Since these blood adiponectin concentration increase promoting and / or decreasing inhibitor, or blood adiponectin concentration increasing and / or decreasing suppressing food and drink, feed has an effect of increasing blood adiponectin concentration and / or decreasing decrease. It can be very useful for the prevention, treatment, and improvement of various pathologies caused by the aforementioned decrease in blood adiponectin concentration.
The lactic acid bacteria used in the present invention have been used for the production of fermented milk and cheese since ancient times, and the blood adiponectin concentration increase promotion and / or decrease inhibitor of the present invention, or the blood adiponectin concentration increase promotion and / or decrease. Inhibitory foods and drinks and feeds are characterized by no safety issues.
Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples. However, these are merely illustrative and the present invention is not limited thereto.

(Preparation of Lactobacillus gasseri culture powder 1)
Reduced skim milk medium (13 wt% skim milk powder, containing 0.5 wt% yeast extract) is sterilized at 95 ° C for 30 minutes, then inoculated with Lactobacillus gasseri SBT2055, and cultured at 37 ° C for 16 hours. The culture was freeze-dried to obtain a culture powder of Lactobacillus gasseri SBT2055. This can be used as it is as an agent for promoting and / or suppressing the increase in blood adiponectin concentration of the present invention.

(Preparation of Lactobacillus gasseri culture powder 2)
Reduced skim milk medium (13 wt% skim milk powder, containing 0.5 wt% yeast extract) was sterilized at 95 ° C for 30 minutes, then inoculated with Lactobacillus gasseri JCM1131 and cultured at 37 ° C for 16 hours. The culture was freeze-dried to obtain a culture powder of Lactobacillus gasseri JCM1131. This can be used as it is as an agent for promoting and / or suppressing the increase in blood adiponectin concentration of the present invention.

[Test Example 1]
(Lactobacillus gasseri culture administration and blood adiponectin measurement)
50 4-week-old Fischer male rats were allowed to freely receive a control diet and bred for 1 week, then divided into groups of 10 each, one group continued to receive the control diet, the other group contained Lactobacillus gasseri ( Lactobacillus gasseri) SBT2055, Lactobacillus gasseri JCM1131, Lactobacillus gasseri ATCC 19992, Lactobacillus casei Lactobacillus casei ATCC11578 and fed for a further 4 weeks Medium adiponectin concentration was measured. There were no differences in body weight, food intake, or fecal weight among the five groups.
Table 1 shows the results obtained by measuring the blood adiponectin concentration. According to this, the concentration of adiponectin in the blood was compared with that in the control food intake group. ) The ATCC11578 diet group maintained a significantly high value. That is, Lactobacillus gasseri SBT2055, Lactobacillus gasseri JCM1131, Lactobacillus gasseri ATCC19992, Lactobacillus casei Lactobacillus casei in a food powder with the addition of Lactobacillus casei ATCC11578 It was confirmed that the concentration was kept constant.

  Based on the above results, foods supplemented with Lactobacillus gasseri culture powder suppressed the decrease in blood adiponectin concentration, which has been shown to increase the risk of cardiovascular disease, and reached an appropriate value. It became clear that there was an effect to maintain.

(Manufacture of tablets)
A liquid culture of Lactobacillus gasseri SBT2055 was centrifuged at 7,000 rpm for 15 minutes at 4 ° C. and washed with sterilized water, and this was repeated three times to obtain washed cells. This was freeze-dried to obtain cell powder. Tablets containing 200 mg of Lactobacillus gasseri SBT2055 cells of the present invention are prepared by mixing 1 part of this powder with 4 parts of skim milk powder, and tableting this mixed powder 1 g at a time using a tableting machine. Was prepared.

(Manufacturing fermented milk)
Lactobacillus gasseri SBT2055 was cultured in MRS liquid medium (Difco). Each culture solution in the logarithmic growth phase was inoculated with 1% in 10% reduced skim milk (115 ° C., sterilized for 20 minutes) supplemented with 0.3% yeast extract to prepare a mother culture. 10% reduced skim milk was added thereto, and 2.5% was added to the yogurt mix heated at 100 ° C. for 10 minutes. Fermentation was performed at 37 ° C., cooling was performed when the lactic acid acidity reached 0.85, the fermentation was terminated, and the fermented milk for blood adiponectin concentration increase and / or decrease inhibitor of the present invention was obtained.

(Manufacture of powder)
After inoculating 5 L of MRS liquid medium (Difco) with Lactobacillus gasseri (Lactobacillus gasseri) SBT2055, static culture was performed at 37 ° C. for 18 hours. After completion of the culture, centrifugation was performed at 7,000 rpm for 15 minutes to obtain 1/50 amount of concentrated cells in the culture solution. Next, the concentrated cells were mixed with the same amount of a dispersion medium containing 10% by weight of skim milk powder and 1% by weight of sodium glutamate, adjusted to pH 7, and then freeze-dried. The obtained lyophilized product was sized with a 60 mesh sieve to produce a lyophilized bacterial powder. In accordance with the provisions of the 13th revised Japanese Pharmacopoeia General Rules for Preparations, “Powder”, 1 g of this freeze-dried bacterial powder is added with 400 g of lactose (JP) and 600 g of potato starch (JP), and mixed uniformly. A powder for promoting and / or suppressing decrease in blood adiponectin concentration was obtained.

(Manufacture of stick health food)
Lactobacillus gasseri SBT2055 culture powder obtained in Example 1 was mixed with 40 g of an equal mixture of vitamin C and citric acid, 100 g of granulated sugar, and 60 g of an equal mixture of corn starch and lactose. . The mixture was packed in a stick-shaped bag to produce a stick-shaped health food for promoting and / or suppressing decrease in blood adiponectin concentration of the present invention.

(Manufacture of natural cheese)
The raw milk with adjusted fat percentage was sterilized by heating at 75 ° C. for 15 seconds, then cooled to 30 ° C., and 0.01% calcium chloride was added. Next, after adding 0.7% of commercially available lactic acid bacteria starter (made by Christian Hansen) and 1% of Lactobacillus gasseri SBT2055 to these raw milk, and adding rennet 0.003% to coagulate the milk Then, the mixture was cut and stirred until the pH reached 6.2 to 6.1, and whey was discharged to obtain curd grains. Furthermore, this curd grain was mold-packed, squeezed, and further salted to produce a natural cheese for promoting and / or suppressing decrease in blood adiponectin concentration of the present invention.

(Manufacture of capsules)
The raw materials were mixed according to the formulation shown in Table 2, granulated and then filled into capsules to produce capsules for promoting and / or suppressing decrease in blood adiponectin concentration of the present invention.

[Table 2]
──────────────────────────
SBT2055 (Example 1) 20.0 (wt%)
Lactose 24.5
Soluble starch 55.0
Magnesium stearate 0.5
──────────────────────────

(Manufacture of beverages)
The ingredients shown in Table 3 were mixed and filled into a container, and then heat sterilized to produce a blood adiponectin concentration increase promotion and / or decrease suppression beverage of the present invention.

[Table 3]
──────────────────────────
SBT2055 (Example 2) 2.5 (wt%)
Sugar 7.5
Citric acid 0.6
Apple juice 10.0
Water 79.4
──────────────────────────

(Manufacture of low fat hard natural cheese)
Several kinds of low-fat hard natural cheeses were produced using raw milk adjusted so that the fat percentage in cheese was 12 to 30%. That is, the raw milk with adjusted fat percentage was sterilized by heating at 75 ° C. for 15 seconds, then cooled to 30 ° C., and 0.01% calcium chloride was added. Next, after adding 0.7% lactic acid bacteria starter (manufactured by Christian Hansen) and 1% Lactobacillus helveticus SBT2171 to these raw milk, and adding rennet 0.003% to coagulate the milk, The mixture was cut and stirred until the pH reached 6.2 to 6.1, and whey was discharged to obtain curd grains. Further, the curd grains were molded, squeezed, and further salted to produce a gouda cheese type low-fat hard natural cheese for increasing and / or suppressing blood adiponectin concentration according to the present invention.

(Manufacturing fermented milk)
Fermented milk was produced using Lactobacillus helveticus SBT2171. Lactobacillus helveticus (Lactobacillus helveticus) SBT2171 cultured in 100 g of skim milk at 37 ° C. for 12 hours was inoculated into 3 kg of the same medium and cultured at 37 ° C. for 12 hours. Using the total amount of milk after culturing as a starter, 100 kg of skimmed milk was fermented at 32 ° C. for 20 hours to obtain fermented milk for promoting and / or suppressing decrease in blood adiponectin concentration of the present invention. The viable count of Lactobacillus helveticus SBT2171 was 8.2 × 10 ⁸ cells / g.

(Manufacture of drink yogurt)
To 43 kg of fermented milk obtained in Example 11, 4 kg of granulated sugar, 3 kg of water and 0.15 kg of pectin were added and homogenized to obtain 50 kg of drink yogurt. This drink yogurt had a mild and favorable flavor, was pH 3.6, and the viable cell count of Lactobacillus helveticus SBT2171 was 4.6 × 10 ⁸ cells / g.

  After adding the same amount of water to 5 kg of the fermented product obtained in the same manner as in Example 11, it was centrifuged at 3,500 × g for 20 minutes with a continuous centrifuge to separate and recover only the cells. In order to remove the non-bacterial components contained in the precipitate, 1 kg of water was added, followed by centrifugation again, and this was repeated three times. Finally, 20 g of Lactobacillus helveticus SBT2171 cells were collected.

[Test Example 2]
(Confirmation of blood adiponectin concentration increase promotion and / or decrease suppression effect)
Using Lactobacillus helveticus cells, the effect of promoting and / or suppressing the decrease of blood adiponectin concentration was confirmed. Animal experiments consisted of 8 4-week-old Fischer male rats per group, a group administered with a diet containing Lactobacillus helveticus (a fungal diet group), and a group administered with a diet not containing a bacterial cell ( Control diet group). In the animal experiment, a control feed was given until the 4th week after breeding, and then a control feed or a fungal feed containing Lactobacillus helveticus was given until the 8th week. Blood was collected at 4th and 8th weeks, and the blood adiponectin concentration was measured using a mouse / rat adiponectin ELISA kit (Otsuka Pharmaceutical Co., Ltd.).
The results are shown in Table 4. According to this, it was clarified that the blood adiponectin concentration in the control diet group decreased with time, whereas that in the fungal diet group increased. That is, it was found that by ingesting Lactobacillus helveticus, the increase in blood adiponectin concentration was promoted or decreased.

[Test Example 3]
(Confirmation of adiponectin increase promotion and / or suppression effect)
Using the cheese obtained in Example 10, the adiponectin increase promotion and / or the decrease suppression action was confirmed. The animal experiment was carried out as 8 groups of 4 week-old Fischer rats, a group to which a diet containing cheese was administered (cheese diet group), and a group to which a control diet without cheese was administered (control diet group). . The control feed uses milk casein as the protein source and butter oil as the lipid source. Based on the results of cheese component analysis (Table 5), the content of general ingredients, major minerals, and vitamin E (α-tocopherol) It mix | blended so that it might become the same as the feed which mix | blended cheese. In the feed mixed with cheese, both protein and lipid were covered only with cheese components.
In the animal experiment, a control feed was given up to 4 weeks after breeding, and then divided into two groups, and a control feed and a cheese feed were given up to 8 weeks. Blood was collected at 4th and 8th weeks, and the blood adiponectin concentration was measured using a mouse / rat adiponectin ELISA kit (Otsuka Pharmaceutical Co., Ltd.).

  The results are shown in Table 6. According to this, it was clarified that the blood adiponectin concentration in the control diet group decreased with time, whereas the cheese diet group increased rather. That is, it was found that the blood adiponectin concentration was increased or decreased by ingesting cheese produced with Lactobacillus helveticus.

  The raw materials were mixed according to the formulation shown in Table 7, and the feed for breeding dogs for promoting and / or suppressing the increase in blood adiponectin concentration of the present invention was produced.

[Table 7]
──────────────────────────
SBT2171 cells 2.5 (wt%)
Nonfat dry milk 13.5
Soybean cake 12.0
Soybean oil 4.0
Corn oil 2.0
Palm oil 27.0
Corn starch 14.0
Flour 9.0
Bran 2.0
Vitamin mixture 9.0
Mineral mixture 2.0
Cellulose 3.0
──────────────────────────

Claims (6)

  Lactobacillus lactic acid bacteria culture and / or blood adiponectin concentration increase promotion and / or reduction inhibitor comprising as an active ingredient.   The Lactobacillus lactic acid bacterium is Lactobacillus gasseri or Lactobacillus helveticus, The blood adiponectin concentration increase promotion and / or decrease inhibitor according to claim 1.   A food and drink for promoting and / or suppressing decrease in blood adiponectin concentration, comprising a culture of Lactobacillus lactic acid bacteria and / or bacterial cells as active ingredients.   Lactobacillus lactic acid bacteria are Lactobacillus gasseri or Lactobacillus helveticus, The food / beverage product for blood-adiponectin density | concentration increase promotion and / or suppression suppression of Claim 3.   A feed for promoting and / or suppressing decrease in blood adiponectin concentration, comprising a lactobacillus lactic acid bacteria culture and / or cells as active ingredients.   The feed for promoting and / or suppressing decrease in blood adiponectin concentration according to claim 5, wherein the Lactobacillus lactic acid bacterium is Lactobacillus gasseri or Lactobacillus helveticus.